24.02.2016
Bayer Aktiengesellschaft DE000BAY0017
DGAP-Adhoc: Bayer Aktiengesellschaft: Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG
Bayer Aktiengesellschaft / Key word(s): Change of Personnel
24.02.2016 10:58
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Leverkusen, February 24, 2016
Effective May 1, 2016, Werner Baumann will become the new Chairman of the
Board of Management of Bayer AG. This was decided by the company's
Supervisory Board at its meeting today. The current CEO of Bayer AG, Dr.
Marijn Dekkers, proposed to the Supervisory Board that his contract be
dissolved effective April 30, 2016, following the Annual Stockholders'
Meeting. The Supervisory Board approved this proposal. Following rapid
implementation of the realignment under Dr. Dekkers' leadership, Bayer is
now entering a new era as a pure Life Science company. That is why the
Supervisory Board believes this is now the right time to hand on
responsibility for managing the company. Dekkers' contract was originally
scheduled to run until December 31, 2016. At the present time, Baumann is
the Board member with responsibility for Strategy and Portfolio Management.
He will retain these functions in the future. Going forward, the Board of
Management of Bayer AG will comprise seven members instead of eight.
Contact:
Mr. Peter Dahlhoff, Bayer AG, Investor Relations, Phone: +49-214-30-33022,
e-mail: [email protected], Fax: 0214-30-96-33022
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
Forward-Looking Statements
This ad-hoc announcement may contain forward-looking statements based on
current assumptions and forecasts made by Bayer management. Various known
and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in Bayer's public reports which are
available on the Bayer website at www.bayer.com. The company assumes no
liability whatsoever to update these forward-looking statements or to
conform them to future events or developments.
24.02.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Bayer Aktiengesellschaft
Kaiser-Wilhelm-Allee 1
51373 Leverkusen
Germany
Phone: +49 (0)214 30-81 013
Fax: +49 (0)21430-9681013
E-mail:
Internet: www.bayer.com
ISIN: DE000BAY0017
WKN: BAY001
Indices: DAX, EURO STOXX 50, Stoxx 50
Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime
Standard), Hamburg, Hanover, Munich, Stuttgart; Terminbörse
EUREX; Madrid, Luxemburg
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Bayer Aktiengesellschaft ISIN: DE000BAY0017 können Sie bei EQS abrufen
Gesundheit , BAY001 , BAYN , XETR:BAYN